2012年12月22日讯 /
生物谷BIOON/ --
Biogen Idec公司宣布在未来三年内将投入超过1000万美元与来自哥伦比亚大学、哈佛大学、罗彻斯特大学以及耶鲁大学的神经系统科学专家合作研究肌萎缩性脊髓侧索硬化症（ASL，又称路格里克氏病）。
Biogen公司 CEO George Scangos将ALS作为公司的一个新的发展平台。事实上,早在2010年8月Scangos就与Knopp Neurosciences 签订了价值3.45亿美元的协议研究治疗ALS的方法，目前该项目正进入后期阶段。
但是公司首席科学家Spyros Artavanis-Tsakonas也承认，研究ALS的研究还面临很多困难。（生物谷Bioon.com）
来源：
http://www.bioon.com/industry/drug/536984.shtml
详细英文报道:
With a new research consortium, Biogen Idec ($BIIB) has expanded its interest in advancing new treatments for a mysterious neurodegenerative disease. Today the company announced the initiative focused on amyotrophic lateral sclerosis (ALS), or Lou Gehrig's disease, with plans to funnel more than $10 million over three years into projects from neuroscience experts at universities such as Columbia, Harvard, Rockefeller and Yale.
Biogen CEO George Scangos has clearly targeted ALS as a growth platform, building on the Weston, MA-based biotech giant's base in neurology with multiple sclerosis therapies such as Avonex and Tysabri. In fact, the first big deal announced under Scangos' term as CEO in August 2010 was a $345 million pact with Knopp Neurosciences to join forces on dexpramipexole, which is now in late-stage development for treating ALS.
"ALS research is a primary area of focus for Biogen Idec, but has proven to be a very difficult disease to understand and treat," Biogen's chief scientist, Spyros Artavanis-Tsakonas, said in a statement.
Artavanis-Tsakonas is helming the new ALS consortium and tackling Biogen's part in the research at his own Harvard lab. The idea behind the effort, according to Biogen, is to gain deeper knowledge of how the disease works and shed light on targets and ways to treat it. And breaking from traditional secretive ways academics conduct research prior to big publications, members of the consortium plan to meet regularly and share their findings.
Biogen and other major biopharma players have made a spate of extramural moves within academia and with other stakeholders to tackle tough diseases such as ALS, which has befuddled researchers and has no definite cause. In an effort to better understand the rare illness--which affects about two in 100,000 people and robs victims of motor function and eventually their lives--Biogen struck an agreement this year with Duke University and Hudson Alpha Institute to sequence the genomes of 1,000 patients with the disorder. That effort will be wrapped into the new consortium.
狗仔卡
发表于 2012-12-25 05:34:57
提升卡
置顶卡
沉默卡
喧嚣卡
变色卡
抢沙发
千斤顶
显身卡
发表于 2012-12-25 06:36:45
